Plural Ring Nitrogens In The Polycyclo Ring System Patents (Class 514/214.02)
-
Publication number: 20150072964Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.Type: ApplicationFiled: April 14, 2013Publication date: March 12, 2015Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
-
Publication number: 20150051192Abstract: A method of preventing drug use relapse by administering an effective amount of an ?3?4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use. A method of preventing drug use relapse due to cue inducement by administering an effective amount of an ?3?4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement. A method of preventing drug use relapse due to cue inducement by modulating the dopaminergic mesolimbic pathway by blocking ?3?4 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala of a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement. A method of preventing drug use relapse by preventing a relapse of drug use during cue inducement.Type: ApplicationFiled: March 25, 2013Publication date: February 19, 2015Inventors: Stanley D. Glick, James E. Polston
-
Publication number: 20150045350Abstract: A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.Type: ApplicationFiled: June 3, 2014Publication date: February 12, 2015Inventor: Lawrence Friedhoff
-
Patent number: 8946206Abstract: Provided herein are methods, drug formulations, and dosing regimens for improving cognitive function in a normal or cognitively impaired subject. For instance, methods provided herein comprise administering a GABAA receptor antagonist so that peak concentration of the GABAA receptor antagonist occurs when the subject is asleep.Type: GrantFiled: December 15, 2011Date of Patent: February 3, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Craig C. Garner, H. Craig Heller, Damien Colas, Daniel Z. Wetmore
-
Patent number: 8940728Abstract: This invention relates noribogaine derivatives, compositions and methods of use thereof.Type: GrantFiled: January 2, 2013Date of Patent: January 27, 2015Assignee: DemeRx, Inc.Inventors: Deborah C. Mash, Richard D. Gless, Jr., Robert M. Moriarty
-
Patent number: 8937061Abstract: This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.Type: GrantFiled: December 7, 2012Date of Patent: January 20, 2015Assignee: DemeRx, Inc.Inventors: Robert M. Moriarty, Deborah C. Mash
-
Patent number: 8921355Abstract: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.Type: GrantFiled: July 8, 2009Date of Patent: December 30, 2014Assignee: Janssen R & D IrelandInventors: Sandrine Marie Helene Vendeville, Pierre Jean-Marie Bernard Raboisson, Tse-I Lin, Abdellah Tahri, Katie Ingrid Eduard Amssoms
-
Publication number: 20140364384Abstract: The present invention relates to the detection of markers in exhaled breath, wherein the detection of the presence or absence of the marker(s) in exhaled breath is used to assess various clinical data, including patient adherence in taking the medication and patient enzymatic (metabolic) competence in metabolizing the medication. An embodiment of the invention comprises a parent therapeutic agent labeled with a marker, where upon metabolism (e.g., via enzymatic action) of the therapeutic agent, the marker becomes volatile or semi-volatile and is present in the breath. In certain related embodiments, the marker contain a deuterium label, which is also present in the breath upon metabolism of the therapeutic agent. In another embodiment of the invention, the therapeutic agent is associated with a taggant (that may be either labeled or unlabeled with deuterium), which in turn will generate a marker in the breath that is easily measurable.Type: ApplicationFiled: April 23, 2014Publication date: December 11, 2014Applicant: University of Florida Research Foundation, Inc.Inventors: Richard J. Melker, Donn Michael Dennis, Christopher D. Batich, Mark S. Gold
-
Publication number: 20140357621Abstract: The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Applicant: Novartis AGInventors: Gary Michael Ksander, Erik Meredith, Lauren Monovich, Julien Papillon, Fariborz Firooznia, Qi-Ying Hu
-
Publication number: 20140349992Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.Type: ApplicationFiled: June 9, 2014Publication date: November 27, 2014Applicant: Sunovion Pharmaceuticals Inc.Inventors: Larry Wendell Hardy, Michele L.R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Patent number: 8895545Abstract: In part, the present invention is directed to antibacterial compounds.Type: GrantFiled: October 4, 2012Date of Patent: November 25, 2014Assignee: Debiopharm International SAInventors: Heinz W. Pauls, Jailall Ramnauth, Peter Sampson, Andras Toro
-
Publication number: 20140343041Abstract: The present invention provides topical ophthalmic formulations comprising a combination of one or more antihistamine agents and optionally one or more vasculature modifying agents such as a ? adrenergic receptor antagonist. Also provided are methods of using the formulations of the invention for treating and/or preventing symptoms associated with migraine headache, and for reducing the frequency, severity and duration of migraine attacks.Type: ApplicationFiled: March 13, 2014Publication date: November 20, 2014Inventors: Matthew J. Chapin, Richard Abelson
-
Publication number: 20140343040Abstract: Provided are compounds having formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as disclosed herein, or a pharmaceutically salt thereof. Pharmaceutical compositions comprising the compounds and methods of their use, for instance in treating senility, senile confusion, psychoses, psychoneuroses when anxiety and nervous tension were present, cerebral arteriosclerosis, nausea, depression, fatigue, debilitation, mild behavioral disorders, irritability, emotional instability, antisocial attitudes, anxiety, vertigo or incontinence, or symptom thereof, or in improving cognitive function in individuals, for instance, in individuals with Down syndrome and other conditions, are also provided.Type: ApplicationFiled: May 3, 2012Publication date: November 20, 2014Inventor: Lyndon Lien
-
Patent number: 8889666Abstract: The present invention provides a new compound that has an inhibitory action against EGFR and that has cell growth inhibitory effects. The present invention further provides a pharmaceutical preparation useful for preventing and/or treating cancer, based on the EGFR inhibitory effect of the compound. A compound represented by the following Formula (I) or a salt thereof.Type: GrantFiled: February 22, 2013Date of Patent: November 18, 2014Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Takeshi Sagara, Satoru Ito, Sachie Otsuki, Katsumasa Nonoshita
-
Publication number: 20140323426Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.Type: ApplicationFiled: May 30, 2014Publication date: October 30, 2014Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia, Chun-Su Yuan
-
Publication number: 20140323399Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.Type: ApplicationFiled: July 8, 2014Publication date: October 30, 2014Inventors: Michael A. Cowley, Anthony A. McKinney, Gary Tollefson
-
Publication number: 20140315839Abstract: Provided is a pest control composition containing a novel iminopyridine derivative and other pest control agents. Provided is a pest control composition containing an iminopyridine derivative represented by the following Formula (I) and at least one of other pest control agents: [in the formula (I), Ar represents a 5- to 6-membered heterocycle which may be substituted, A represents a heterocycle having a 5- to 10-membered unsaturated bond including one or more nitrogen atoms, and has an imino group substituted with an R group at a position adjacent to the nitrogen atom present on the cycle, Y represents hydrogen, halogen and the like, and R represents any one of groups represented by the following Formulae (a) to (e), (y) or (z)].Type: ApplicationFiled: July 1, 2014Publication date: October 23, 2014Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Ryo HORIKOSHI, Yasumichi ONOZAKI, Satoshi NAKAMURA, Masahiro NOMURA, Makoto MATSUMURA, Masaaki MITOMI
-
Publication number: 20140315837Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Inventors: Deborah C. Mash, Richard D. Gless
-
Publication number: 20140315891Abstract: This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and/or stress using such compounds and/or pharmaceutical compositions.Type: ApplicationFiled: April 21, 2014Publication date: October 23, 2014Inventor: Deborah C. Mash
-
Publication number: 20140303144Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?2B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.Type: ApplicationFiled: February 17, 2012Publication date: October 9, 2014Applicant: Medivation Technologies, Inc.Inventors: Andrew Asher Protter, Sarvajit Chakravarty
-
Publication number: 20140303148Abstract: The present invention provides a pharmaceutical composition for inhibiting angiogenesis containing a plant-derived natural compound which can be effective for preventing or treating disorders or diseases associated with angiogenesis. The compound used as an active ingredient in the pharmaceutical composition of the present invention suppresses VEGF-induced angiogenic responses without cytotoxicity at a low concentration by inhibiting the expression of an anti-angiogenic factor (for example, VEGF), and thus remarkably improves the safety of a drug.Type: ApplicationFiled: November 28, 2012Publication date: October 9, 2014Inventors: Ho Jeong Kwon, Yong Hyo Kim
-
Patent number: 8853201Abstract: Disclosed herein are sulfate esters of noribogaine or 9,17 dihydronoribogaine, and pharmaceutically acceptable salts of each thereof, pharmaceutical compositions comprising such compounds, and methods of their use, including in treating addiction and/or pain.Type: GrantFiled: December 7, 2012Date of Patent: October 7, 2014Assignee: DemeRx, Inc.Inventors: Richard D. Gless, Jr., Robert M. Moriarty
-
Publication number: 20140296209Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B—The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.Type: ApplicationFiled: February 17, 2012Publication date: October 2, 2014Applicant: MEDIVATION TECHNOLOGIES, INC.Inventors: Andrew Asher Protter, Sarvajit Chakravarty
-
Publication number: 20140294805Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.Type: ApplicationFiled: September 2, 2011Publication date: October 2, 2014Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Peter Dragovich, Francis Gosselin, Bingsong Han, Jian Lin, Dominic J. Reynolds, Bruce Roth, Chase C. Smith, Zhongguo Wang, Po-Wai Yuen, Xiaozhang Zheng
-
Publication number: 20140296210Abstract: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a noncompetitive GABAA ionophore blocker is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.Type: ApplicationFiled: April 2, 2014Publication date: October 2, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Craig C. Garner, Fabian J. Fernandez
-
Patent number: 8846659Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.Type: GrantFiled: December 7, 2011Date of Patent: September 30, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Kevin Peese, B. Narasimhulu Naidu, Manoj Patel, Chen Li, Michael A. Walker
-
Publication number: 20140288056Abstract: The disclosure provides a method to administer noribogaine to a human patient having drug addiction in dosages that provide efficacy without leading to any significant deleterious clinical signs.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Applicant: DEMERX, INC.Inventor: Lawrence Friedhoff
-
Publication number: 20140275012Abstract: The present invention encompasses compounds of the formula (I) wherein the groups ring A and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Todd BOSANAC, Michael J. BURKE, Darren DISALVO, Wang MAO, John WESTBROOK
-
Publication number: 20140255386Abstract: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.Type: ApplicationFiled: July 24, 2012Publication date: September 11, 2014Applicants: NORTH CAROLINA STATE UNIVERSITY, THE WISTAR INSTITUTEInventors: Qihong Huang, Alexander Deiters, Kiranmai Gumireddy
-
Publication number: 20140235618Abstract: The present invention provides methods for the treatment of atopic dermatitis and other inflammatory skin disorders. It has been found that topical application of alcaftadine compositions is useful for prophylaxis and symptomatic management of atopic dermatitis and associated symptoms.Type: ApplicationFiled: February 19, 2014Publication date: August 21, 2014Applicant: Allergan, Inc.Inventors: Michael D. Cheung, Dinusha Lalwani
-
Patent number: 8796260Abstract: Compounds of Formula I: I (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.Type: GrantFiled: February 6, 2009Date of Patent: August 5, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Howard G. Selnick, Ian M. Bell
-
Publication number: 20140206670Abstract: The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.Type: ApplicationFiled: March 19, 2014Publication date: July 24, 2014Applicant: Pfizer Inc.Inventors: David James Dooley, Mark John Field, Richard Griffith Williams
-
Publication number: 20140200209Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicants: ViiV Healthcare Company, Shionogi & Co., Ltd.Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
-
Patent number: 8772301Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.Type: GrantFiled: December 17, 2010Date of Patent: July 8, 2014Assignee: Sunovion Pharmaceuticals, Inc.Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Kerry L. Spear, Lakshmi D. Saraswat
-
Patent number: 8765737Abstract: Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.Type: GrantFiled: May 10, 2011Date of Patent: July 1, 2014Assignee: DemeRx, Inc.Inventors: Deborah C. Mash, Richard D. Gless, Jr.
-
Publication number: 20140178503Abstract: The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: Auspex Pharmaceuticals, Inc.Inventors: Ronald C. Newbold, Chengzhi Zhang
-
Publication number: 20140179682Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.Type: ApplicationFiled: June 8, 2012Publication date: June 26, 2014Applicant: SUNOVION PHARMACEUTICALS INC.Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
-
Publication number: 20140179685Abstract: This invention relates noribogaine derivatives, compositions and methods of use thereof.Type: ApplicationFiled: January 29, 2013Publication date: June 26, 2014Inventors: Deborah C. Mash, Richard D. Gless, JR., Robert M. Moriarty
-
Publication number: 20140179684Abstract: This invention relates noribogaine derivatives, compositions and methods of use thereof.Type: ApplicationFiled: January 2, 2013Publication date: June 26, 2014Applicant: DemeRx, Inc.Inventors: Deborah C. Mash, Richard D. Gless, JR., Robert M. Moriarty
-
Publication number: 20140171417Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: December 17, 2013Publication date: June 19, 2014Applicant: NOVARTIS AGInventors: Mahbub AHMED, Alexander ASHALL-KELLY, Louisa GUERITZ, Jeffrey MCKENNA, Joseph MCKENNA, Simon MUTTON, Rakesh PARMAR, Jon SHEPHERD, Paul WRIGHT
-
Publication number: 20140162964Abstract: Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in the treatment of progressive dementia or brain degenerative diseases.Type: ApplicationFiled: December 2, 2013Publication date: June 12, 2014Applicant: NOVARTIS AGInventors: Volker Brinkmann, Nicole Kaneider, Christian J. Wiedermann
-
Patent number: 8741891Abstract: This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and/or stress using such compounds and/or pharmaceutical compositions.Type: GrantFiled: June 21, 2011Date of Patent: June 3, 2014Assignee: DemeRx, Inc.Inventor: Deborah C. Mash
-
Patent number: 8729067Abstract: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a noncompetitive GABAA ionophore blocker is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.Type: GrantFiled: May 22, 2007Date of Patent: May 20, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Craig C. Garner, Fabian J. Fernandez
-
Publication number: 20140120185Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.Type: ApplicationFiled: April 4, 2012Publication date: May 1, 2014Inventors: Tsuyoshi Hirose, Kenji Maeda, Tetsuro Kikuchi, Masafumi Toda
-
Publication number: 20140113878Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.Type: ApplicationFiled: August 4, 2011Publication date: April 24, 2014Inventors: Deborah C. Mash, Richard D. Gless, JR.
-
Publication number: 20140107102Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 8, 2013Publication date: April 17, 2014Applicant: Allergan, Inc.Inventors: Jagdish Parasrampuria, Avner Ingerman, Frans Janssens, Anton Megens
-
Publication number: 20140107101Abstract: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.Type: ApplicationFiled: March 15, 2013Publication date: April 17, 2014Applicant: JANSSEN R&D IRELANDInventor: Janssen R&D Ireland
-
Publication number: 20140088085Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.Type: ApplicationFiled: January 12, 2012Publication date: March 27, 2014Applicants: ARRAY BIOPHARMA, INC, VENTIRX PHARMACEUTICALS, INCInventors: Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones, James Jeffry Howbert, Robert Hershberg, Joseph P. Lyssikatos, Hong Woon Yang
-
Publication number: 20140080799Abstract: Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1?), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGF? pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1?), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGF? pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.Type: ApplicationFiled: September 20, 2013Publication date: March 20, 2014Applicant: Jasco Pharmaceuticals, LLCInventors: Carmen M. Baldino, Justin L. Caserta, Chee-Seng Lee, Robert B. Nicewonger, Yvonne L. Flanders, Stephane A. Dumas
-
Patent number: 8664215Abstract: Compositions, kits, and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 26, 2007Date of Patent: March 4, 2014Assignee: Vistakon Pharmaceuticals, LLCInventors: Avner Ingerman, Frans Janssens, Anton Megens, Mark B. Abelson